BEVERLY PATTERSON: Open Payments
NPI 1124146626 · HAMPTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,085 in 48 payments from 15 companies in 2025. Trend: 2023 $1,035 · 2024 $762 · 2025 $1,085
Food & beverage: $1,078Education: $6
| Company | Payments | Amount |
|---|---|---|
| BioCryst US Sales Co., LLC | 8 | $235 |
| GENZYME CORPORATION | 7 | $215 |
| Regeneron Healthcare Solutions, Inc. | 8 | $197 |
| GlaxoSmithKline, LLC. | 5 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Genentech USA, Inc. | 2 | $58 |
| CSL Behring | 3 | $48 |
| Cycle Pharmaceuticals Inc | 3 | $47 |
| Optinose US, Inc. | 2 | $31 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $30 |
Products named: DUPIXENT, ORLADEYO, NUCALA, TAKHZYRO, Xolair, Sajazir, Xhance, NEFFY.
Industry payments across VA — which companies pay providers there.
